Most Recent
IP Australia has rejected US fintech Block's bid to patent a method for adjusting animations to enable a large volume of point of sale applications, finding the invention was a mere scheme that did not meet the manner of manufacture test for patentability.
Marlow Foods, maker of popular meat-replacement product Quorn, has lost an application to patent a vegan burger that contains a non-egg binding agent, with IP Australia saying the recipe lacked inventiveness.
IP Australia has rejected an application by US technology company Block to patent a mobile payment method, saying it does not describe a manner of manufacture -- the threshold requirement tripping up many claimed computer-implemented inventions.
Intellectual property law firm Spicer Spicer has lost its opposition to Coca-Cola’s patent application for soft drinks and syrups containing an artificial sweetener known as Reb X, with an IP Australia delegate rejecting the firm’s argument the patent was not inventive.
The Sydney Opera House is challenging a ruling that denied its opposition to a trade mark application filed by a China-Australia trade association that featured an image of the opera house sails together with the Great Wall of China.
German pharmaceutical giant Boehringer has partially succeeded in its opposition to several vaccine patents filed by animal health company Zoetis, used to treat pneumonia in pigs.
LG Electronics has lost its opposition to Samsung Electronic's registration for its 'Samsung QLED' trade mark despite IP Australia acknowledging that Samsung's phones did not contain QLED technology.
The television broadcaster behind the cult cooking show Iron Chef has lost its opposition to an 'Iron Chef' trade mark application by an Aussie food delivery app developer, despite IP Australia finding the show had garnered a "moderate reputation" among Australian viewers.
US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.